Xenon Pharmaceuticals Statistics
Total Valuation
XENE has a market cap or net worth of $2.34 billion. The enterprise value is $1.66 billion.
Important Dates
The next estimated earnings date is Monday, August 11, 2025, after market close.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XENE has 76.73 million shares outstanding. The number of shares has increased by 11.90% in one year.
| Current Share Class | 76.73M |
| Shares Outstanding | 76.73M |
| Shares Change (YoY) | +11.90% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 97.96% |
| Float | 70.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 312.05 |
| Forward PS | n/a |
| PB Ratio | 3.32 |
| P/TBV Ratio | 3.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 221.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.66, with a Debt / Equity ratio of 0.01.
| Current Ratio | 17.66 |
| Quick Ratio | 17.43 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.60% and return on invested capital (ROIC) is -22.74%.
| Return on Equity (ROE) | -31.60% |
| Return on Assets (ROA) | -22.03% |
| Return on Invested Capital (ROIC) | -22.74% |
| Return on Capital Employed (ROCE) | -41.19% |
| Revenue Per Employee | $22,936 |
| Profits Per Employee | -$768,948 |
| Employee Count | 327 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.07M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.33% in the last 52 weeks. The beta is 1.16, so XENE's price volatility has been higher than the market average.
| Beta (5Y) | 1.16 |
| 52-Week Price Change | -29.33% |
| 50-Day Moving Average | 31.38 |
| 200-Day Moving Average | 36.55 |
| Relative Strength Index (RSI) | 41.56 |
| Average Volume (20 Days) | 819,180 |
Short Selling Information
The latest short interest is 6.51 million, so 8.48% of the outstanding shares have been sold short.
| Short Interest | 6.51M |
| Short Previous Month | 7.39M |
| Short % of Shares Out | 8.48% |
| Short % of Float | 9.18% |
| Short Ratio (days to cover) | 4.31 |
Income Statement
In the last 12 months, XENE had revenue of $7.50 million and -$251.45 million in losses. Loss per share was -$3.22.
| Revenue | 7.50M |
| Gross Profit | -219.84M |
| Operating Income | -293.00M |
| Pretax Income | -199.34M |
| Net Income | -251.45M |
| EBITDA | -290.36M |
| EBIT | -293.00M |
| Loss Per Share | -$3.22 |
Full Income StatementBalance Sheet
The company has $549.63 million in cash and $8.68 million in debt, giving a net cash position of $682.45 million or $8.89 per share.
| Cash & Cash Equivalents | 549.63M |
| Total Debt | 8.68M |
| Net Cash | 682.45M |
| Net Cash Per Share | $8.89 |
| Equity (Book Value) | 703.96M |
| Book Value Per Share | 9.19 |
| Working Capital | 533.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$196.85 million and capital expenditures -$2.93 million, giving a free cash flow of -$199.78 million.
| Operating Cash Flow | -196.85M |
| Capital Expenditures | -2.93M |
| Free Cash Flow | -199.78M |
| FCF Per Share | -$2.60 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -3,906.60% |
| Pretax Margin | -3,406.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XENE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.90% |
| Shareholder Yield | -11.90% |
| Earnings Yield | -10.74% |
| FCF Yield | -8.54% |
Dividend DetailsAnalyst Forecast
The average price target for XENE is $54.82, which is 79.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $54.82 |
| Price Target Difference | 79.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -26.05% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XENE has an Altman Z-Score of 43.97 and a Piotroski F-Score of 1.
| Altman Z-Score | 43.97 |
| Piotroski F-Score | 1 |
